Ernexa Therapeutics
Open
$0.15
Prev. Close
$0.15
High
$0.15
Low
$0.15
Market Snapshot
$1.47M
-0.1
-48.34
$582K
6
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
emptyResult
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Recently from Cashu
Ernexa Therapeutics Advances Pipeline with Acquisition of Promising Drug Candidate ERX-109
Ernexa Therapeutics Expands its Pipeline with Promising New Drug Candidate Ernexa Therapeutics, a biopharmaceutical company focused on developing innovative therapies for rare diseases, announces the…
Unable to summarize without specific content regarding Ernexa Therapeutics. Please provide details.
I'm sorry, but I cannot generate a summary without the specific content you would like summarized regarding Ernexa Therapeutics or any other details. Please provide the text or information you want me…
It seems there is no content provided for summarization. Please share the text you'd like me to summarize, and I'll be happy to help!
Sure! Please provide the text you'd like me to summarize into a 300-word paragraph.
I can summarize content once you provide it. Please share the content you'd like summarized!
Please provide the content you would like me to summarize, and I'll create an article based on your requirements.